AIDA COMPLETES TRIALS OF ANTI-TUMOR DRUG

Chinese drugmaker Aida Pharmaceuticals announced that it has successfully concluded the Phase I trials for its anti-tumor drug Rh-Apo2L.

The trials included 20 patients with advanced-stage malignant tumors. Researchers found that trials support the belief that Rh-Apo2L reduces the tumor size of non-Hodgkin's lymphoma, sarcoma and adrenal gland cortical tumors. Additionally, the drug affects the tumor size of non-small-cell lung cancer, colorectal cancer and parotid gland capsule adenocarcinoma.